The failure of antimotion sickness medication to improve reading in developmental dyslexia: results of a randomized trial.

Author(s): Fagan JE, Kaplan BJ, Raymond JE, Edgington ES

Affiliation(s): Department of Pediatrics, University of Calgary, Alberta, Canada.

Publication date & source: 1988-12, J Dev Behav Pediatr., 9(6):359-66.

Publication type: Clinical Trial; Randomized Controlled Trial

Although there have been no randomized clinical trials of the efficacy of antimotion sickness medication treatment of developmental dyslexia, some children are treated in this way. We have performed two evaluations of such treatments. In Experiment 1, 12 children participated in a double-blind within-subject crossover design to test the acute (2-day) administration of four preparations: 10 mg methylphenidate, 12.5 mg meclizine, both methylphenidate and meclizine, or placebo. Improvements obtained with each drug were scattered across measures of reading fluency, balance and coordination, and eye movements, suggesting that a chronic trial would be justified. In Experiment 2, six children from Experiment 1 received 12.5 mg meclizine b.i.d. for 3 months and placebo for 3 months in a double-blind within-subject crossover design. Meclizine had no effect on reading, but it significantly improved ocular motor stability during steady fixation. This study thus failed to support the hypothesis that meclizine is of benefit in developmental dyslexia.